Abstract 2061P
Background
Patients’ concerns have become more complicated, while the advancements in cancer treatments have improved clinical outcomes. This study aims to comprehensively explore the concerns of cancer patients and to elucidate their interrelationships.
Methods
A fact-finding survey was conducted with 300 cancer patients (male; 127, female; 173) using a 74-item questionnaire. The questionnaire included comprehensive items (rated from 0 [none] to 3 [severe]) related to the concerns of cancer patients. Correlation network analysis was performed to visualize the association between the patients’ concerns. Degree centrality was used to assess network centrality, and the Girvan–Newman algorithm was used to detect communities.
Results
Cancer types were as follows: breast cancer (n=84), gastrointestinal cancer (n=82), urologic cancer (n=52), cholangiopancreatic cancer (n=44), gynecologic cancer (n=20), and others (n=18). The mean overall score was significantly higher in females than in males (30.4 vs. 22.5, p<0.01). The most frequent concerns were physical decline (81.7 %), fatigue (80.5 %), muscle weakness in the limbs (65.9 %). In the overall network, the concerns with the highest centrality score were muscle weakness in the limbs (0.151), nutritional management (0.123) and fatigue (0.082). The network was classified into three communities: 1) physical decline, including 21 items such as muscle weakness, nutritional management, and fatigue; 2) changes in appearance, including 8 items such as pigmentation and hair loss; 3) social support, including 11 items such as employment and finances. The network analysis by gender showed that the highest centered item was sex life (0.123) in men, and depression (0.137) and anxiety (0.110) in women.
Conclusions
This study illustrated that cancer-related fatigue and weakness were the most frequently and numerous interrelated concerns that plagued patients with cancer. Furthermore, they formed a wide-ranging network with other concerns. Our study also showed that the structure of the network differed between the sexes. A multidisciplinary approach may be necessary to comprehensively solve interrelated patient concerns.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
Y. Miura: Financial Interests, Personal, Invited Speaker: Takeda, MSD, Bristol Myers Squibb, Ono Pharmaceutical, Merck BioPharma, Eisai, Astellas Pharma; Financial Interests, Institutional, Local PI: Ono Pharmaceutical, MSD. All other authors have declared no conflicts of interest.
Resources from the same session
2028TiP - Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3
Presenter: Julien Mazieres
Session: Poster session 06
2029TiP - Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors
Presenter: Sreenivasa Chandana
Session: Poster session 06
2035P - Routine biomarker monitoring does not replace comprehensive clinical assessment in the detection of immunotherapy induced myocarditis
Presenter: Alexandra Johnson
Session: Poster session 06
2036P - Prevalence and risk evaluation of cardiovascular disease among newly diagnosed prostate cancer population in China
Presenter: Weiyu Zhang
Session: Poster session 06
2037P - Prehabilitation as a strategy to improve postoperative outcomes in frail cancer patients undergoing elective surgery: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Poster session 06
2039P - Primary endpoints of confirmatory randomized controlled trials for older patients with cancer: A scoping review
Presenter: Tomonori Mizutani
Session: Poster session 06
2041P - The prevalence of hematologic adverse events (HAEs) and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients (pts) with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitor (PARPi), with or without a germline BRCA pathogenic variant
Presenter: Carmine Valenza
Session: Poster session 06
2042P - Improving breast cancer outcomes for indigenous women
Presenter: Vita Christie
Session: Poster session 06
2043P - Can Charlson Comorbidity Index (CCI) and Clinical Frailty Scale (CFS) assessments predict survival in octogenarians with colorectal cancer?
Presenter: Neda Nikolic
Session: Poster session 06
2044P - Bloodstream infections (BSI) in cancer patients: Epidemiology, antibiotic therapy and risk factors related to mortality
Presenter: Carlos López Jiménez
Session: Poster session 06